Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.

BACKGROUND: The aim of the present study was to evaluate the future cumulative risk of prostate cancer in relation to levels of prostate-specific antigen (PSA) in blood and to determine whether this information could be used to individualize the PSA testing interval. METHODS: The study included 5855...

Full description

Bibliographic Details
Main Authors:	Aus, G, Damber, J, Khatami, A, Lilja, H, Stranne, J, Hugosson, J
Format:	Journal article
Language:	English
Published:	2005

Similar Items

Erratum: PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section (International Journal of Cancer (2007) 120, (170-174))
by: Khatami, A, et al.
Published: (2007)

Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
by: Hugosson, J, et al.
Published: (2004)

Mortality results from the Goteborg randomised population-based prostate-cancer screening trial.
by: Hugosson, J, et al.
Published: (2010)

Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
by: Hugosson, J, et al.
Published: (2003)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
by: Hugosson, J, et al.
Published: (2003)

Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial.
by: Aus, G, et al.
Published: (2007)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
by: Aus, G, et al.
Published: (2003)

Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.
by: Zackrisson, B, et al.
Published: (2003)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section.
by: Khatami, A, et al.
Published: (2007)

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden.
by: Hugosson, J, et al.
Published: (2000)

Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden.
by: Bruun, L, et al.
Published: (2005)

Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden.
by: Vickers, A, et al.
Published: (2010)

Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort.
by: Vickers, A, et al.
Published: (2009)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees.
by: Bergdahl, A, et al.
Published: (2009)

Screening for prostate cancer.
by: Carlsson, S, et al.
Published: (2012)

Screening for prostate cancer: To the editor
by: Carlsson, S, et al.
Published: (2012)

Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy.
by: Vickers, A, et al.
Published: (2010)

Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection.
by: Zackrisson, B, et al.
Published: (2003)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
by: Becker, C, et al.
Published: (2000)

The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
by: Zackrisson, B, et al.
Published: (2004)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
by: Roobol, M, et al.
Published: (2009)

Increase in percent free prostate-specific antigen in men with chronic kidney disease.
by: Bruun, L, et al.
Published: (2009)

Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.
by: Nurmikko, P, et al.
Published: (2001)

Biology of prostate-specific antigen
by: Lilja, H
Published: (2003)

Biology of prostate-specific antigen.
by: Lilja, H
Published: (2003)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden.
by: Vickers, A, et al.
Published: (2008)

Lead time associated with screening for prostate cancer.
by: Törnblom, M, et al.
Published: (2004)

The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group.
by: Vickers, A, et al.
Published: (2010)

A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
by: Scardino Peter T, et al.
Published: (2008-07-01)

[Isoforms of free prostate-specific antigen]
by: Haese, A, et al.
Published: (2004)

Isoforms of free prostate-specific antigen
by: Haese, A, et al.
Published: (2004)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Optimal use of prostate specific antigen for prostate cancer screening
by: Miočinović Ranko, et al.
Published: (2013-01-01)

Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands.
by: Auvinen, A, et al.
Published: (2009)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
by: Avery, K, et al.
Published: (2012)

Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy
by: Avery, K, et al.
Published: (2012)